These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 32542729)

  • 1. Switching costs in competitive health insurance markets: The role of insurers' pricing strategies.
    Lamiraud K; Stadelmann P
    Health Econ; 2020 Sep; 29(9):992-1012. PubMed ID: 32542729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching benefits and costs in competitive health insurance markets: A conceptual framework and empirical evidence from the Netherlands.
    Duijmelinck DM; Mosca I; van de Ven WP
    Health Policy; 2015 May; 119(5):664-71. PubMed ID: 25530069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supplementary insurance as a switching cost for basic health insurance: Empirical results from the Netherlands.
    Willemse-Duijmelinck DMID; van de Ven WPMM; Mosca I
    Health Policy; 2017 Oct; 121(10):1085-1092. PubMed ID: 28855064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of supplementary health insurance on switching behaviour: evidence from Swiss data.
    Dormont B; Geoffard PY; Lamiraud K
    Health Econ; 2009 Nov; 18(11):1339-56. PubMed ID: 19267356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching health insurers: the role of price, quality and consumer information search.
    Boonen LH; Laske-Aldershof T; Schut FT
    Eur J Health Econ; 2016 Apr; 17(3):339-53. PubMed ID: 25820635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pricing behaviour of nonprofit insurers in a weakly competitive social health insurance market.
    Douven RC; Schut FT
    J Health Econ; 2011 Mar; 30(2):439-49. PubMed ID: 21295365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the medical loss ratio a good target measure for regulation in the individual market for health insurance?
    Karaca-Mandic P; Abraham JM; Simon K
    Health Econ; 2015 Jan; 24(1):55-74. PubMed ID: 24123608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching gains and health plan price elasticities: 20 years of managed competition reforms in The Netherlands.
    Douven R; Katona K; T Schut F; Shestalova V
    Eur J Health Econ; 2017 Nov; 18(8):1047-1064. PubMed ID: 28243775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Price-Directed Search, Product Differentiation and Competition.
    Obradovits M; Plaickner P
    Rev Ind Organ; 2023; 63(3):317-348. PubMed ID: 37786646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are Health Insurance Markets Competitive?
    Dafny LS
    Am Econ Rev; 2010 Sep; 100(4):1399-431. PubMed ID: 29517879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consumer price sensitivity in Dutch health insurance.
    van Dijk M; Pomp M; Douven R; Laske-Aldershof T; Schut E; de Boer W; de Boo A
    Int J Health Care Finance Econ; 2008 Dec; 8(4):225-44. PubMed ID: 18709549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulated Medicare Advantage And Marketplace Individual Health Insurance Markets Rely On Insurer Competition.
    Frank RG; McGuire TG
    Health Aff (Millwood); 2017 Sep; 36(9):1578-1584. PubMed ID: 28874484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Market power in the United States red meatpacking industry.
    Koontz SR
    Vet Clin North Am Food Anim Pract; 2003 Jul; 19(2):519-44. PubMed ID: 12951745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does managed competition constrain hospitals' contract prices? Evidence from the Netherlands.
    Douven R; Burger M; Schut F
    Health Econ Policy Law; 2020 Jul; 15(3):341-354. PubMed ID: 30973119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How can the regulator show evidence of (no) risk selection in health insurance markets? Conceptual framework and empirical evidence.
    van de Ven WP; van Vliet RC; van Kleef RC
    Eur J Health Econ; 2017 Mar; 18(2):167-180. PubMed ID: 26837411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managed competition and consumer price sensitivity in social health insurance.
    Schut FT; Hassink WH
    J Health Econ; 2002 Nov; 21(6):1009-29. PubMed ID: 12475123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching insurer in the Irish voluntary health insurance market: determinants, incentives, and risk equalization.
    Keegan C; Teljeur C; Turner B; Thomas S
    Eur J Health Econ; 2016 Sep; 17(7):823-31. PubMed ID: 26359243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scope and Incentives for Risk Selection in Health Insurance Markets With Regulated Competition: A Conceptual Framework and International Comparison.
    van Kleef RC; Reuser M; McGuire TG; Armstrong J; Beck K; Brammli-Greenberg S; Ellis RP; Paolucci F; Schokkaert E; Wasem J
    Med Care Res Rev; 2024 Jun; 81(3):175-194. PubMed ID: 38284550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching rates in health insurance markets decrease with age: empirical evidence and policy implications from the Netherlands.
    Duijmelinck DM; van de Ven WP
    Health Econ Policy Law; 2016 Apr; 11(2):141-59. PubMed ID: 26173559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.